|
WO2017181285A1
|
|
Purine compounds and method for the treatment of cancer
|
|
WO2017177336A1
|
|
Rhamnolipid coated nanoscale zerovalent iron emulsions and method of use thereof
|
|
WO2017066884A1
|
|
Fluidic circuits and methods for bacterial screening
|
|
US2017072071A1
|
|
Inflammation-enabling polypeptides and uses thereof
|
|
WO2017024407A1
|
|
Peptidic tgf-beta antagonists
|
|
WO2017005774A2
|
|
Use of oleylphosphocholine (olpc) for peventing or treating cryptosporidiosis
|
|
WO2016183678A1
|
|
Solar energy harvesting and reversible hydrogen storage methods and systems
|
|
CA2927200A1
|
|
Sulfidated nanoscale zerovalent iron and method of use thereof
|
|
US2017297931A1
|
|
Sulfidated nanoscale zerovalent iron and method of use thereof
|
|
US9783428B1
|
|
Production of high strength hydrochloric acid from calcium chloride feed streams by crystallization
|
|
WO2016145539A1
|
|
Electrochemical flow cell and ultramicroelectrode
|
|
US2016326585A1
|
|
Inflammation-enabling polypeptides and uses thereof
|
|
CA2907348A1
|
|
Multilayered bone graft and method of making same
|
|
US2015369819A1
|
|
TMEM120A ion channel modulator
|
|
US2017197873A1
|
|
Methods and systems relating to enhancing material toughness
|
|
US2017202525A1
|
|
Methods and systems for anatomical structure and transcatheter device visualization
|
|
CA2968995A1
|
|
Anti-ganglioside compound for targeting cancer and generating antibodies
|
|
US2014329767A1
|
|
Methods for treating type-2 diabetes and obesity
|
|
CN105492459A
|
|
Modified INGAP peptides for treating diabetes
|
|
US2014315965A1
|
|
Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer
|
